Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study

NCT02239393 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL: Mesenchymal Stem Cells

Sponsor

Ottawa Hospital Research Institute